Cytopia Starts Dosing Patients In First Suite Of Phase II Clinical Studies For Vascular Disrupting Agent, CYT997 - Quick Facts

(RTTNews) - Australian biotechnology co., Cytopia Ltd. (CYTPF.PK) announced that it has commenced dosing patients in first of suite of Phase II clinical studies for vascular disrupting agent or VDA, CYT997. These studies will investigate the activity of anti-cancer compound in specific cancer types with high unmet medical need and poor prognoses.

Cytopia commenced dosing in its first Phase II efficacy study in patients with relapsed or refractory multiple myeloma in January 2008. Cytopia also intends to file Orphan Drug Designation application in United States for CYT997 in multiple myeloma, within three months.

Cytopia expects to commence Phase II study for CYT997 in glioblastoma multiforme or GBM during second quarter of 2008. It is anticipated that 25 to 30 patients will be enrolled into this study for 18 month period. The company expects interim data for Phase Ib/II trial in GBM by June 2009 with final data in late 2009.

The company specified that it is also undertaking feasibility analysis for Phase II study in mesothelioma patients who have failed currently approved drug, Alimta. The company predicts to file appropriate regulatory submissions to support this study in the third quarter of 2008.

For comments and feedback: contact editorial@rttnews.com Copyright(c) 2008 RealTimeTraders.com, Inc. All Rights Reserved

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index